Reflecting on 2024, we’re grateful to everyone who has been part of our journey. This year, we initiated multiple clinical trials targeting various cancer indications with specific genetic signatures. ?? Wishing you all a joyous holiday season and a prosperous 2025 filled with health, happiness, and new opportunities. ?? Thank you for being a part of our journey! For more information, email us at [email protected]
Jubilant Therapeutics Inc
生物技术
Yardley，Pennsylvania 3,379 位关注者
Leveraging innovation to deliver precision medicines
关于我们
Jubilant Therapeutics is a patient-focused biopharmaceutical company advancing potent and selective small molecule modulators to address specific unmet medical needs in oncology and autoimmune diseases. The company’s leadership and scientific team are science-driven executives with global pharma background and experience in advancing innovative drug candidates into the clinic. Jubilant Therapeutics is headquartered in the U.S. with independent board and management, guided by globally renowned KOLs and SAB. Key Therapeutic Areas ? Oncology ? Auto-immune Disorders Portfolio ? Novel PAD4 inhibitors targeting auto-immune disorders ? Dual LSD1/HDAC6 inhibitors targeting cancer ? Novel small molecule PD-L1 inhibitors ? Novel brain penetrating PRMT5 inhibitors targeting cancer
- 网站
-
https://www.jubilanttx.com
Jubilant Therapeutics Inc的外部链接
- 所属行业
- 生物技术
- 规模
- 11-50 人
- 总部
- Yardley，Pennsylvania
- 类型
- 私人持股
- 创立
- 2019
地点
-
主要
获取路线
790, Township Line Road, Suite 175
US，Pennsylvania，Yardley，19067
Jubilant Therapeutics Inc员工
-
Syed Kazmi
President and CEO at Jubilant Therapeutics Inc.
-
Shyam Pattabiraman
Chief Financial Officer | Biotech | Pharma | Jubilant Therapeutics/ Pharmova | PwC Consulting | London School of Economics | Columbia Business School
-
Mohd Zainuddin
Biology/Early development/DMPK/Clinical Pharmacology
-
Santosh kumar M.
Director Finance : Jubilant Therapeutics India Limited
动态
-
?? Exciting News from Jubilant Therapeutics! ?? We are thrilled to announce the first patient dosing in our global clinical trials for two potential groundbreaking therapies: #JBI802: A first-in-class, orally administered #CoREST inhibitor, now in Phase I/II trials for Essential Thrombocythemia and Myeloproliferative Neoplasms (#MPN) with #thrombocytosis #JBI778: A potential best-in-class, brain-penetrant #PRMT5 inhibitor, now in Phase I trials for mEGFR #NSCLC, #IDH+ High Grade Glioma (#HGG), Adenoid Cystic Carcinoma (#ACC) These advancements mark a significant step in our mission to develop precision oral medicines with enhanced safety and efficacy. Stay tuned for more updates as we continue to transform patientcare in oncology and autoimmune diseases. For more information: https://lnkd.in/ge5vYSzF #lsd1 #hdac6 #nsclc #osimertinib #thrombocythemia
-
-
?? Exciting News from Jubilant Therapeutics! ?? We are thrilled to announce the first patient dosing in our global clinical trials for two potential groundbreaking therapies: #JBI802: A first-in-class, orally administered #CoREST inhibitor, now in Phase I/II trials for Essential Thrombocythemia and Myeloproliferative Neoplasms (#MPN) with #thrombocytosis #JBI778: A potential best-in-class, brain-penetrant #PRMT5 inhibitor, now in Phase I trials for mEGFR #NSCLC, #IDH+ High Grade Glioma (#HGG), Adenoid Cystic Carcinoma (#ACC) These advancements mark a significant step in our mission to develop precision oral medicines with enhanced safety and efficacy. Stay tuned for more updates as we continue to transform patientcare in oncology and autoimmune diseases. For more information: https://lnkd.in/ge5vYSzF #lsd1 #hdac6 #nsclc #osimertinib #thrombocythemia
-
-
Exciting news! ?? Our CEO, Syed Kazmi, CMO, Melda ?am?lgil Dolan, and CFO, Shyam Pattabiraman, presented at the Raymond James Biotech Private Company Showcase on July 17, 2024. We were thrilled to share insights about Jubilant Therapeutics and our innovative clinical oncology programs targeting unmet needs in specific patient populations. #Biotech #Oncology #Innovation #coREST #PRMT5 #NSCLC #Thrombocythemia #Glioma #SCLC #MPN
-
-
Join our DMPK and Toxicology expert, Mohd Zainuddin, at #AACR 2024 ! He’ll be there to connect with fellow researchers and share insights about our innovative oncology programs. If you’re attending and interested in discussing our research, don’t hesitate to contact us at [email protected]. We look forward to engaging conversations! #AACR #NSCLC #coREST #LSD1 #HDAC6 #PRMT5 #Thrombocythemia #stk11
-